This week’s research reinforces several consistent themes in aspergillosis: ongoing diagnostic confusion (particularly with tuberculosis and cancer), increasing movement toward precision medicine, and continued development of both antifungal therapies and biomarkers. There is also a growing emphasis on host-pathogen interactions rather than fungal burden alone.
Key Highlights
- Isavuconazole levels can become unexpectedly high due to genetics and drug interactions.
- Chronic pulmonary aspergillosis (CPA) can mimic lung cancer, risking delayed diagnosis.
- New biomarker (EDN) for ABPA shows promise for diagnosis and monitoring.
- Azole resistance research highlights differences between Aspergillus species.
- New antifungal approaches emerging (olorofim, nitroxoline).
- Host response is central – fibroblasts and immune pathways actively influence disease.
- TB vs aspergillosis confusion persists in real-world settings.
Contents
- Clinical & Diagnostic Studies
- Treatment & Pharmacology
- Biology, Immunology & Resistance
- Biomarkers & Diagnostics
- Wider Context
Clinical & Diagnostic Studies
CPA mistaken for lung cancer
Paper: PubMed
A case report describes chronic pulmonary aspergillosis presenting as suspected lung malignancy in a patient with asthma and ABPA overlap.
Why this matters: CPA continues to be misdiagnosed due to tumour-like imaging appearances. This reinforces the need to consider fungal disease in patients with underlying lung conditions.
Invasive sinus aspergillosis causing bone destruction
Paper: Free full text
Granulomatous invasive aspergillosis led to facial bone destruction and neurological symptoms.
Why this matters: Delayed diagnosis of invasive disease can lead to severe structural damage. Early imaging and specialist input are critical.
Aspergillus infection in suspected TB patients
Paper: PubMed
Study shows overlap between tuberculosis and aspergillosis in symptomatic patients.
Why this matters: Persistent global issue—shared symptoms delay correct diagnosis and treatment, particularly relevant for CPA pathways.
Invasive aspergillosis in critical illness
Paper: PubMed
Case of invasive pulmonary aspergillosis in a patient with severe viral illness.
Why this matters: Reinforces that aspergillosis is not limited to traditional risk groups and can complicate severe systemic illness.
Treatment & Pharmacology
Isavuconazole toxicity linked to genetics
Paper: Free full text
Case report of supratherapeutic isavuconazole levels linked to CYP3A5 genotype and interacting medications.
Why this matters: Even “predictable” antifungals show variability. Supports therapeutic drug monitoring and future personalised dosing approaches.
Olorofim pharmacokinetics
Paper: PubMed
Study demonstrates tissue distribution of olorofim in preclinical models.
Why this matters: Supports ongoing development of a key next-generation antifungal, particularly for resistant disease.
Nitroxoline shows antifungal activity
Paper: PubMed
Repurposed drug demonstrates activity against Aspergillus via copper disruption and oxidative stress.
Why this matters: Highlights potential for non-azole antifungal strategies in future treatment.
Biology, Immunology & Resistance
Azole resistance and Aspergillus genomics
Paper: PubMed
Genomic study of Aspergillus section Fumigati explores resistance mechanisms and pathogenicity.
Why this matters: Different species may respond differently to antifungals—accurate identification is increasingly important.
Fibroblasts actively support lung defence
Paper: PubMed
Study shows fibroblasts contribute to immune defence and tissue repair during infection.
Why this matters: Disease outcomes depend on host response, not just fungal burden—important for future therapies.
Immune pathway targeting in fungal keratitis
Paper: PubMed
PIM1 inhibition reduces inflammation via STING pathway signalling.
Why this matters: Supports growing interest in targeting immune pathways alongside antifungal therapy.
Biomarkers & Diagnostics
Eosinophil-derived neurotoxin (EDN) in ABPA
Paper: PubMed
EDN proposed as a biomarker for allergic bronchopulmonary aspergillosis.
Why this matters: Could improve diagnosis and monitoring, helping distinguish ABPA from asthma or sensitisation alone.
Commentary on ISHAM ABPA guidelines
Paper: PubMed
Discussion of updated international guidance on ABPA diagnosis and management.
Why this matters: Highlights ongoing refinement of diagnostic criteria and classification systems.
Wider Context
Fungal extracellular vesicles
Paper: PubMed
Review of fungal vesicles in pathogenesis and host interaction.
Why this matters: Emerging area that may influence future diagnostics and therapies.
Aspergillosis in broader disease settings
Why this matters: Aspergillosis continues to appear across a wide range of conditions, particularly in critically ill or immunocompromised patients.
Overall Interpretation
This week’s literature reinforces several strategic priorities:
- Earlier and more accurate diagnosis remains essential, particularly in distinguishing CPA from TB and cancer.
- Precision medicine is advancing, with growing roles for pharmacogenomics, drug monitoring, and species-level identification.
- New antifungal options are progressing, but remain largely in development.
- Host response is increasingly recognised as central to disease progression and outcomes.
Overall, the field continues to move toward more personalised, biology-driven approaches to diagnosis and management.
Latest News posts
News archive